S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

OncLive® On Air - Un pódcast de OncLive® On Air

Podcast artwork

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Visit the podcast's native language site